| Code | CSB-RA015007MB14HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ofatumumab, targeting MS4A1 (Membrane Spanning 4-Domains A1), also known as CD20. MS4A1 is a B-cell specific surface antigen expressed throughout B-cell development from pre-B cells to mature B lymphocytes, though absent on plasma cells. This transmembrane protein plays a crucial role in regulating B-cell activation, proliferation, and differentiation through calcium channel activity and signal transduction pathways. MS4A1 is critically implicated in B-cell malignancies including non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as autoimmune disorders such as multiple sclerosis and rheumatoid arthritis.
Ofatumumab is a fully humanized anti-CD20 monoclonal antibody that binds to a distinct epitope on the MS4A1 molecule, inducing potent B-cell depletion through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This biosimilar provides researchers with a valuable tool for investigating B-cell biology, exploring mechanisms of B-cell mediated diseases, evaluating therapeutic strategies for autoimmune conditions and hematological malignancies, and studying immune system regulation in various experimental models.
There are currently no reviews for this product.